Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin

Human Gene Therapy Clinical Development

Volumn 26, Issue 3, 2015, Pages 165-176

  Ye, Guo Jie ^a   Budzynski, Ewa ^b   Sonnentag, Peter ^b   Miller, Paul E ^c   Sharma, Alok K ^b   Ver Hoeve, James N ^c   Howard, Kellie ^d   Knop, David R ^a   Chulay, Jeffrey D ^a  

^a APPLIED GENETIC TECHNOLOGIES CORPORATION   (United States)

^b 206 Carnegie Center   (United States)

^c OSOD ^*  (United States)

^d LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; RETINOSCHISIN; VIRUS ANTIBODY; EYE PROTEIN; RS1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE SEGMENT; ARTICLE; AUTOPSY; BLOOD CLOTTING; CELL LABELING; CLINICAL CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; EYE EXAMINATION; EYE INFLAMMATION; HEMATOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; INTRAOCULAR PRESSURE; LOW DRUG DOSE; MACACA FASCICULARIS; MALE; MONONUCLEAR CELL; NERVE CELL; NONHUMAN; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA GANGLION CELL; RETINOSCHISIS; TOPICAL TREATMENT; VIRUS RECOMBINANT; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; BLOOD; CELL LINE; CLINICAL PROTOCOL; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOKINETICS; REPORTER GENE; RETINA; T LYMPHOCYTE; TIME FACTOR; TISSUE DISTRIBUTION; TRANSGENE; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CLINICAL PROTOCOLS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; EYE PROTEINS; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAVITREAL INJECTIONS; MACACA FASCICULARIS; MALE; RETINA; RETINOSCHISIS; T-LYMPHOCYTES; TIME FACTORS; TISSUE DISTRIBUTION; TRANSGENES; VIRUS SHEDDING;

EID: 85006216324     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2015.076     Document Type: Article

References (34)

1. George ND, Yates JR, Moore AT. X linked retinoschisis. Br J Ophthalmol 1995;79:697-702.
2. Tantri A, Vrabec TR, Cu-Unjieng A, et al. X-linked retinoschisis: A clinical and molecular genetic review. Surv Ophthalmol 2004;49:214-230.
3. Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res 2012;31: 195-212.
4. Apushkin MA, Fishman GA. Use of dorzolamide for patients with X-linked retinoschisis. Retina 2006;26:741-745.
5. 'Genead MA, Fishman GA, Walia S. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Arch Ophthalmol 2010;128:190-197.
6. Ghajarnia M, Gorin MB. Acetazolamide in the treatment of X-linked retinoschisis maculopathy. Arch Ophthalmol 2007;125:571-573.
7. Khandhadia S, Trump D, Menon G, Lotery AJ. Xlinked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype. Eye (Lond) 2011;25:922-928.
8. Walia S, Fishman GA, Molday RS, et al. Relation of response to treatment with dorzolamide in Xlinked retinoschisis to the mechanism of functional loss in retinoschisin. Am J Ophthalmol 2009;147:111-115.
9. Zeng Y, Takada Y, Kjellstrom S, et al. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis. Invest Ophthalmol Vis Sci 2004;45:3279-3285.
10. Min SH, Molday LL, Seeliger MW, et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. Mol Ther 2005;12: 644-651.
11. Kjellstrom S, Bush RA, Zeng Y, et al. Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: Long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 2007;48:3837-3845.
12. Janssen A, Min SH, Molday LL, et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther 2008;16: 1010-1017.
13. Takada Y, Vijayasarathy C, Zeng Y, et al. Synaptic pathology in retinoschisis knockout (Rs1-/y) mouse retina and modification by rAAV-Rs1 gene delivery. Invest Ophthalmol Vis Sci 2008;49:3677-3686.
14. Park TK, Wu Z, Kjellstrom S, et al. Intravitreal delivery of AAV8 retinoschisin results in cell typespecific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 2009;16:916-926.
15. Byrne LC, Ozturk BE, Lee T, et al. Retinoschisin gene therapy in photoreceptors, Muller glia or all retinal cells in the Rs1h-/- mouse. Gene Ther 2014;21:585-559.
16. Song S, Embury J, Laipis PJ, et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2001;8:1299-1306.
17. Petrs-Silva H, Dinculescu A, Li Q, et al. Highefficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;17:463-471.
18. Petrs-Silva H, Yasumura D, Matthes MT, et al. Suppression of rds expression by siRNA and gene replacement strategies for gene therapy using rAAV vector. Adv Exp Med Biol 2012;723:215-223.
19. Apushkin MA, Fishman GA, Janowicz MJ. Correlation of optical coherence tomography findings with visual acuity and macular lesions in patients with X-linked retinoschisis. Ophthalmology 2005;112: 495-501.
20. Thomas DL, Wang L, Niamke J, et al. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther 2009;20:861-870.
21. Chulay JD, Ye GJ, Thomas DL, et al. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther 2011;22: 155-165.
22. Martin PL, Miller PE, Mata M, Christian BJ. Ocular inflammation in cynomolgus macaques following intravenous administration of a human monoclonal antibody. Int J Toxicol. 2009;28:5-16.
23. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516.
24. Jacobson SG, Boye SL, Aleman TS, et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 2006;17:845-858.
25. Lin J, Calcedo R, Vandenberghe LH, et al. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 2008;19:663-669.
26. Maguire AM, High KA, Auricchio A, et al. Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 doseescalation trial. Lancet 2009;374:1597-1605.
27. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: Safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012;130:9-24.
28. Bainbridge JW, Mehat MS, Sundaram V, et al. Longterm effect of gene therapy on Leber's congenital amaurosis. N Engl J Med 2015;372:1887-1897.
29. Sikkink SK, Biswas S, Parry NR, et al. X-linked retinoschisis: An update. J Med Genet 2007;44:225-232.
30. Maclachlan TK, Lukason M, Collins M, et al. Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Mol Ther 2011;19:326-334.
31. Heier J, Campochiaro P, Dugel P, et al. Preliminary results of phase I study with AAV 2-sFLT01 as gene therapy for treatment of exudative age-related macular degeneration. Paper presented at Retina Society Annual Meeting, September 12, 2014, Philadelphia, PA.
32. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha-1 antitrypsin: Interim results. Hum Gene Ther 2011;22:1239-1247.
33. Mueller C, Chulay JD, Trapnell BC, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest 2013;123:5310-5318.
34. AGTC. Safety and efficacy of rAAV-hRS1 in patients with X-linked retinoschisis (XLRS). www.clinicaltrials.gov/ct2/show/NCT02416622 (accessed September 2, 2015).